Dr. Maria Teresa Landi
Senior Investigator, Integrative Tumor Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
Dr. Landi is an M.D., Ph.D. with training in clinical oncology and molecular epidemiology and tenured Senior investigator at the National Cancer Institute, NIH.
She has focused her research on the environmental and genetic determinants of lung cancer and melanoma, and more recently on the genomic landscape of these tumors.
In lung cancer, she is currently leading two large population-based studies and uses next-generation sequencing and genome-wide analyses to explore lung cancer etiology and clonal evolution.
In her melanoma research, she investigates the relationship of UV radiation, genetic susceptibility and other host factors in population studies and in melanoma-prone families.
Title: Sherlock-Lung: Tracing lung cancer mutational processes in never smokers
Summary: Lung cancer in never smokers includes approximately 10-25% of all lung cancers worldwide, ranks among the most common causes of cancer mortality, and has a distinct natural history, restricted histological subtype (almost exclusively adenocarcinoma), different profile of oncogenic mutations, and response to targeted therapy compared to lung cancer in smokers.
Although few risk factors are known to contribute to the etiology of lung cancer in never smokers, a large fraction of cancer cases cannot be explained by established environmental and genetic risk factors, highlighting the need for research in this area.
One promising approach to identify the etiological factors involved in lung tumorigenesis in never smokers is based on the study of the “mutational signatures” that the exogeneous and endogenous processes leave on the tumor tissue and surrounding areas. I will describe the Sherlock-Lung study that was designed at the National Cancer Institute, NIH to implement this approach.
I will present preliminary results and possibilities for collaboration.
Donate to Cancer Research
All donations to the IACR go directly towards supporting early-stage oncology scientific researchers in their work.
IACR 2023 Carer’s Bursary €300
Apply for funding towards additional costs of care while attending conference. Five Bursaries Available.
Registration/ Membership for IACR 2023
Registration for the 59th Annual Conference in the Radisson Blu hotel, Athlone is Now Open.
EACR Membership is Included
The IACR is an affiliated national society and its members benefit from full membership of the EACR.
Biomedical Session Abstracts
Deadline: Midnight, Friday, 20th January 2023
- Patrick Johnston Lay submission category is now closed
- Late Breaking Abstracts submitted to the Biomedical Sessions will be considered for Display Poster Presentation.
Social Nursing and Allied Health (SNAH) Abstracts
Deadline: Midnight, Monday, 9th January 2023
SNAH abstract submissions will remain open until Monday 9th January.
Please contact Sinead on: firstname.lastname@example.org
Irish Association for Cancer Research (IACR) is a registered charity on the Register of Charitable Organisations.
Registered Charity Number (RCN): 20030117